drugset / Trial / NCT06596252
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Timeline
- Start
- 2021-05-21
- Primary completion
- 2026-12
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 0.5 mg | — |
| Subject | Budesonide | Small molecule | 1 mg | — |
| Subject | Budesonide | Small molecule | 2 mg | — |